November/December 2011

When a new generic comes to market, we need to think not only about the financial implications but also about the message conveyed to patients.

Fingolimod, a first-line, once-daily oral disease-modifying therapy for relapsing-remitting multiple sclerosis, has the lowest cost per relapse avoided compared with other first-line agents.

The Phaseal closed-system transfer device can extend the beyond-use date of pharmaceuticals, thereby reducing waste.

There were no signifi cant differences in mean low-density lipoprotein cholesterol levels after patients were converted from fl uvastatin to pravastatin therapy.

WHO'S commitment to addressing the impact of 4 common noncommunicable diseases will ultimately lead to improvements for patients with a broad range of chronic conditions.

Uptake of the new oral agents gilenya and Ampyra may be expected to increase rapidly in the future, if for largely different reasons.

Evaluating the relationships between chronic kidney disease and cardiovascular disease and strategies to improve outcomes.